[关键词]
[摘要]
目的 探讨红花黄色素联合美托洛尔治疗冠心病心力衰竭的临床疗效。方法 选取2016年7月-2017年7月在商丘市第一人民医院进行治疗的冠心病心力衰竭患者82例,按照用药的差别分为对照组(41例)和治疗组(41例)。对照组口服酒石酸美托洛尔片,起始剂量6.25 mg/次,2次/d,可耐受情况下,隔周增加6.25~12.5 mg/次,2次/d,最大剂量不超过300~400 mg/d;治疗组在对照组的基础上静脉滴注注射用红花黄色素,100 mg加入100 mL生理盐水,1次/d。两组均治疗2周。评价两组患者临床疗效,同时比较治疗前后两组患者心功能指标和血清学指标。结果 治疗后,对照组临床有效率为78.05%,显著低于治疗组的95.12%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组左心室收缩末内径(LVEDD)、左心室收缩末容量(LVESV)、左心室舒张末内径(LVESD)均明显下降,左心室射血分数(LVEE)明显升高,同组比较差异具有统计学意义(P<0.05);且治疗组这些心功能指标明显优于对照组(P<0.05)。治疗后,两组血清超敏C反应蛋白(hs-CRP)、N-末端B型脑钠肽前体(NT-proBNP)、肌钙蛋白T(cTnT)、GDF-15水平均显著降低(P<0.05),且治疗组这些血清学指标明显低于对照组(P<0.05)。结论 红花黄色素联合美托洛尔治疗冠心病心力衰竭有利于患者心功能改善,降低心肌重塑风险,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Safflor Yellow for injection combined with metoprolol in treatment of heart failure of coronary heart disease. Methods Patients (82 cases) with heart failure of coronary heart disease in the First People's Hospital of Shangqiu from July 2016 to July 2017 were divided into control (41 cases) and treatment (41 cases) groups according to different treatment. Patients in the control group were po administered with Metoprolol Tartrate Tablets, the initial dose was 6.25 mg/time, twice daily, then fortnightly increased with 6.25-12.5 mg/time, twice daily, and the maximum dose was less than 300-400 mg/d. Patients in the treatment group were iv administered with Safflor Yellow for injection on the basis of the control group, 10 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.05%, which was significantly lower than 95.12% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the LVEDD, LVESV and LVESD levels in two groups were significantly decreased, the LVEE levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the cardiac function indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the serum hs-CRP, NT-proBNP, cTnT and GDF-15 levels in two groups were significantly decreased (P<0.05), and the serological indexes in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Safflor Yellow for injection combined with metoprolol in treatment of heart failure of coronary heart disease can significantly improve cardiac function and reduce the myocardial remodeling risk, which has a certain clinical application value.
[中图分类号]
[基金项目]